Single-dose oral ampoule containing cyproheptadine hydrochloride
A single-dose oral ampoule of Cyproheptadine Hydrochloride addresses tolerability and dosing inaccuracies by using a hydrochloride salt form in a sealed package, ensuring precise dosing and microbial safety, enhancing compliance and convenience.
Patent Information
- Application Number
- PCT/EG2025/050021
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-06-04
- Publication Date
- 2026-11-19
AI Technical Summary
Current pharmaceutical forms of Cyproheptadine Hydrochloride, such as tablets and syrups, face challenges including poor tolerability in pediatric and geriatric populations, inaccurate dosing in home settings, microbial contamination risks, potential toxicity from preservatives, and inconsistent global availability, compromising safety and compliance.
A single-dose, ready-to-drink oral ampoule formulation of Cyproheptadine Hydrochloride in a sealed, unit-dose package, optimized for dose accuracy, microbial safety, and patient compliance, using the hydrochloride salt form to enhance solubility and stability, and avoiding preservatives through aseptic manufacturing.
The single-dose ampoule ensures precise dosing, reduces microbial risks, eliminates the need for preservatives, and improves patient compliance, particularly in vulnerable populations, aligning with regulatory standards for safety and convenience.
Smart Images

Figure IMGF000009_0001
Abstract
Description
[0001] Single-Dose Oral Ampoule Containing Cyproheptadine Hydrochloride
[0002] 1. Technical Field
[0003] The present invention relates to the field of pharmaceutical technology. More specifically, it concerns a novel single-use, ready-to-drink oral dosage form comprising Cyproheptadine Hydrochloride in an aqueous solution form, designed for improved patient compliance and dosage accuracy.
[0004] 2. Prior Art
[0005] Cyproheptadine Hydrochloride is a first-generation antihistamine widely prescribed for the treatment of allergic reactions and appetite stimulation. While effective pharmacologically, its current pharmaceutical forms — primarily oral tablets and syrups — present multiple limitations that compromise safety, accuracy, and patient compliance, particularly in pediatric, geriatric, and dysphagic populations.
[0006] 1. Difficulty Swallowing Tablets in Pediatric and Geriatric Populations
[0007] Numerous studies demonstrate that solid oral dosage forms like tablets are poorly tolerated by certain populations:
[0008] • A study from Cincinnati Children's Hospital found that over 26% of children struggle to swallow pills, often leading to skipped doses or alternative, less effective administration methods (Carnaby et al., 2015).1
[0009] • In elderly patients, a systematic review noted that 14% of communitydwelling seniors have swallowing difficulties. Additionally, 25-33% of care providers report altering tablets (e.g., crushing or splitting) to enable administration, which can compromise drug stability and dosage accuracy (Stegemann et al., 2012).2
[0010] 2. Inaccurate Dosing with Syrups in Home Settings
[0011] Liquid medications offer ease of swallowing, but introduce high risk of dose inaccuracy, especially when administered at home by caregivers:
[0012] • A systematic review published in Pediatrics revealed that over 80% of medication errors involving children outside hospitals were associated with liquid medications (Yin et al., 2015).3
[0013] • In a study involving 2,110 caregivers, 84.4% made at least one dosing error when administering syrups. Errors were most common when using measuring cups (43%), compared to oral syringes (16%), and the majority involved overdosing (Yin et al., 2016).4
[0014] • 3. Microbial Contamination Risks in Multi-Dose Syrup Bottles
[0015] Multi-use syrups are vulnerable to microbial contamination due to repeated exposure to air and handling:
[0016] • A 2022 study in Syria found that 26% of tested pediatric syrups exceeded microbial load limits, posing significant safety risks (Al-Mardini et al., 2022).5
[0017] • In 2017, the U.S. FDA issued a national recall of pediatric syrups contaminated with Burkholderia cepacia, which can cause life-threatening infections, especially in immunocompromised individuals.
[0018] 2017 Safety Alert
[0019] 4. Use of Preservatives and Associated Health Risks
[0020] To prevent contamination, syrups require relatively high concentrations of chemical preservatives, which may be unsafe for certain groups:
[0021] • Preservatives like benzyl alcohol have been associated with “gasping syndrome” in neonates, a potentially fatal condition resulting from metabolic immaturity (Gershanik et al., 1982).6
[0022] • Other agents, such as parabens and sodium benzoate, are linked to hypersensitivity reactions and possible endocrine disruption, especially with long-term exposure in children (Amin et al., 2019).7
[0023] 5. Limited Market Availability of Liquid Syrup Formulations
[0024] Although Cyproheptadine is a globally used molecule, liquid formulations are inconsistently available across markets:
[0025] • In Europe, licensed oral solutions are absent in many countries; access is typically limited to tablets.
[0026] • In the MENA region, syrup forms are often discontinued or inconsistently supplied, forcing reliance on tablet manipulation or compounded products.
[0027] • In some countries (e.g., Egypt, Saudi Arabia), several Cyproheptadine syrups have been pulled from the market, creating access gaps.
[0028] This fragmented access restricts clinicians’ ability to prescribe appropriate forms for vulnerable patients, particularly children and those with swallowing impairments.
[0029] 3. Technical Problem in Prior Art
[0030] The evidence above demonstrates clear limitations in the current pharmaceutical landscape for Cyproheptadine Hydrochloride:
[0031] • Poor tolerability of tablets among pediatric and elderly patients.
[0032] • High error rates in home-based syrup dosing.
[0033] • Microbial risks in multi-use liquid containers.
[0034] • Potential toxicity from common preservatives.
[0035] • Global inconsistency in syrup availability.
[0036] These challenges justify the development of a novel single-dose, flavored, ready-to-drink oral ampoule containing Cyproheptadine HC1. Such a formulation
[0037] enhances dose accuracy, patient safety, and accessibility — addressing real unmet needs in clinical practice.
[0038] 4. Summary of the Invention
[0039] This invention provides a single-dose oral liquid formulation of Cyproheptadine Hydrochloride, packaged in a sealed, ready-to-drink ampoule designed for pediatric and adult use. The formulation is optimized for dose accuracy, microbial safety, and patient compliance, especially in populations who cannot tolerate tablets or multi-dose syrups.
[0040] 5. Detailed Technical Description of the Invention
[0041] This invention provides a single-dose oral liquid formulation of
[0042] Cyproheptadine Hydrochloride, packaged in a sealed, unit-dose ampoule designed for improved safety and compliance.
[0043] The formulation contains little to no added preservative, leveraging the single-use packaging and aseptic manufacturing to achieve microbial stability. Regulatory and clinical guidelines advocate avoiding preservatives in infant and toddler medications whenever possible (Rouaz et al., 2021)8
[0044] By delivering each dose in a sterile, one-time-use ampoule, the invention circumvents the need for heavy preservation - an approach aligned with EMA recommendations that single-use formulations be preservative-free whenever feasible.9
[0045] Packaged in a single-dose ampoule, the product offers significant advantages in accuracy and hygiene. Each ampoule contains a pre-measured unit dose of cyproheptadine hcl, eliminating caregiver reliance on teaspoons or measuring cups, studies have found that nearly 40% of parents incorrectly measure liquid doses when using household spoons. (nih.govnichd.nih.gov10)
[0046] By providing a pre-measured dose, the mono-dose ampoule ensures dose precision and consistency, greatly reducing the risk of under- or overdosing. Unit-dose oral delivery systems like this are known to enhance medication safety and compliance: they remove the need for dose preparation, thereby minimizing administration errors and improving convenience for caregivers.11
[0047] In hospital and home settings alike, unit-dose packaging has been shown to streamline medication administration and prevent contamination of multi-use bottles.12
[0048] Each ampoule is intended for one-time use and is discarded after opening, which prevents microbial ingress or cross-contamination between doses. This design is inherently more hygienic than multi-dose syrup bottles that are repeatedly opened, and it aligns with healthcare strategies to improve safety by using single-unit packaging (Smith et al., 2020). Additionally, because each ampoule is sealed until use, the formulation avoids repeated exposure to air and light, preserving drug potency and flavor integrity over its shelf-life.
[0049] In this invention, each dose is sealed in its own container and intended to be used immediately upon opening, which means there is no opportunity for microbial ingress during use and no need for the formulation to remain antimicrobial after initial opening (there is no “second dose” from the same container). Thus, we have avoided adding preservative to the formulation whenever manufacturing and shelf stability conditions permit.
[0050] The selection of Cyproheptadine Hydrochloride (HC1) as the salt form for the single-dose oral ampoule formulation is grounded in its favorable physicochemical and pharmacokinetic properties, which are crucial for developing a stable, effective, and patient- friendly oral liquid dosage form.
[0051] A. . Enhanced Aqueous Solubility
[0052] Cyproheptadine, in its base form, exhibits poor water solubility, posing challenges for oral liquid formulations. Converting it to its hydrochloride salt significantly improves its solubility in aqueous media, facilitating the development of clear and homogeneous solutions. This enhancement is crucial for ensuring consistent dosing and bioavailability in pediatric patients.
[0053] B. Improved Chemical Stability
[0054] The hydrochloride salt form offers superior chemical stability compared to the free base. Studies have demonstrated that Cyproheptadine HC1 solutions remain chemically stable for at least 180 days when stored at room temperature, maintaining consistent pH and physical appearance.13
[0055] C. Favorable Pharmacokinetic Profile
[0056] Cyproheptadine HC1 demonstrates reliable absorption when administered orally, with a terminal half-life of approximately 8.6 hours. This pharmacokinetic profile supports sustained therapeutic levels, reducing the frequency of dosing and enhancing patient compliance.
[0057] D. Compatibility with Pediatric Formulations
[0058] The hydrochloride salt's improved solubility and stability make it particularly suitable for pediatric formulations, where liquid dosage forms are often preferred. It allows for precise dosing adjustments based on age and weight, ensuring safety and efficacy in younger populations.
[0059] E. Regulatory Acceptance
[0060] Cyproheptadine Hydrochloride is a well-established pharmaceutical ingredient with a history of regulatory approval in various formulations, including oral liquids. Its recognized safety and efficacy profiles streamline the approval process for new formulations, facilitating timely access to the market.
[0061] Guidelines- Based Recommended Dosage by Age Group :
[0062] a) Children:
[0063] • 2 to 6 years: 2 mg (half an ampoule ) twice daily
[0064] • 7 to 14 years: 4 mg (10 mL) once or twice daily
[0065] b) Adults and Adolescents >14 years:
[0066] • Starting dose: 4 mg (10 mL) two to three times daily.
[0067] Reference:
[0068] - FDA Label - Cyproheptadine Hydrochloride Tablets USP
[0069] -eMPR - Cyproheptadine Prescription & Dosage Information
[0070] -Medscape - Cyproheptadine Dosing and Uses
[0071] 6. Advantages of the Invention
[0072] This invention provides a scientifically optimized, regulatorily compliant, and patient-centered formulation of Cyproheptadine HC1 in a single-dose oral ampoule. It enhances therapeutic safety and convenience by:
[0073] 1. Accurate Dosing
[0074] Each ampoule contains a precisely measured therapeutic dose (e.g., 2-4 mg), eliminating the risk of dosing errors commonly associated with syrups that require household measuring tools. This enhances treatment safety, particularly in pediatric and geriatric populations.
[0075] 2. Improved Patient Compliance
[0076] 3. Enhanced Microbial Safety
[0077] Unlike multi-use syrups that are prone to contamination after opening, the singleuse ampoule is aseptically filled and sealed, significantly reducing microbial risk. This approach aligns with regulatory guidance favoring preservative-free formulations when using single-dose packaging (EMA, 2014).
[0078] 4. Reduced Need for Preservatives
[0079] Due to the unit-dose design and aseptic manufacturing, the formulation requires no or minimal preservatives, addressing safety concerns for children and reducing potential hypersensitivity reactions.
[0080] 5. Convenient and Hygienic Administration
[0081] The ampoule is portable, lightweight, and easy to use without the need for additional dosing tools. It’s ideal for on-the-go use, home administration, or in clinical settings requiring fast, single-use dispensing.
[0082] 6. Regulatory Alignment and Pediatric Suitability
[0083] The product complies with FDA and EMA guidelines on age-appropriate formulation, excipient safety, and child-friendly packaging. Its design reflects current best practices for pediatric drug development (FDA ICH Ell(Rl), EMA 2013).
[0084] 7. Fields of Application
[0085] • Pediatric medicine
[0086] • Geriatric medicine
[0087] • Appetite stimulation
[0088] • Allergy management
[0089] 8. Best Mode for Carrying Out the Invention
[0090] A Cyproheptadine HC1 solution is prepared and adjusted to a pH of 4.5-6.0.
[0091] Sweeteners and flavoring agents are added. The solution is then aseptically filled into sterile, single-use plastic or glass ampoules using appropriate liquid filling equipment. The final product undergoes quality control to ensure dose uniformity and compliance with microbial limits.
[0092] References
[0093]
Claims
AMENDED CLAIMSreceived by the International Bureau on 10 September 2026 (10.09.2026)
1. An oral pharmaceutical dosage form of CyproheptadineHydrochloride, comprising an aqueous solution of Cyproheptadine Hydrochloride sealed in a single-use, ready-to-drink ampoule or sachet, wherein each ampoule or sachet contains a pre-measured unit dose of 2 mg to 4 mg of Cyproheptadine Hydrochloride in a volume of 5 mL to 10 mL.
2. The oral pharmaceutical dosage form of CyproheptadineHydrochloride according to claim 1, wherein the aqueous solution is a flavored, ready-to-drink liquid formulation having a pH of 4.5 to 6.0.
3. The oral pharmaceutical dosage form of CyproheptadineHydrochloride according to claim 1, wherein the formulation is preservative-free or contains minimal levels of preservatives, and wherein the ampoule or sachet is aseptically filled and sealed.
4. The oral pharmaceutical dosage form of CyproheptadineHydrochloride according to claim 1, wherein the ampoule or sachet is adapted for direct oral administration without reconstitution, dilution, or external measuring tools, and is intended to be discarded after a single use.
5. The oral pharmaceutical dosage form of CyproheptadineHydrochloride according to claim 1, wherein the pre-measured unit dose is 2 mg of Cyproheptadine Hydrochloride in 5 mL, or 4 mg of Cyproheptadine Hydrochloride in 10 mL.[0001]Statement under Article 19(1)[0002]Statement Under Article 19(1) PCT (Rule 46.4)The amendments to the claims are made in response to the International Search Report and the Written Opinion of the International Searching Authority mailed on 08 September 2025. Claim 1 as amended now begins with the indefinite article and incorporates the pre-measured unit dose of 2 mg to 4 mg of Cyproheptadine Hydrochloride in a volume of 5 mL to 10 mL, sealed in a single-use, ready-to-drink ampoule or sachet. Dependent claims 2-5 repeat the preamble of claim 1 verbatim, in line with the observations in Box No. VIII of the Written Opinion. The amended claims define a purposive combination of technical features: the hydrochloride salt in aqueous solution; a narrow, pediatrically appropriate dose window selected from the very broad dose ranges of the prior art; a defined dose-to-volume presentation permitting direct swallowing of the complete dose; a flavored formulation at pH 4.5-6.0; aseptic filling and sealing; and a preservative-free or minimal-preservative composition enabled by the single-use sealed format. These features cooperate to produce a combined technical effect — accurate unit dosing without measuring devices and microbiological safety in use without reliance on antimicrobial preservatives — which is neither disclosed nor suggested by documents D1-D4 cited in the International Search Report, whether taken alone or in combination. None of the cited documents addresses the technical problem underlying the invention, and no motivation exists in the cited art to select and combine their teachings so as to arrive at the claimed dosage form; the claimed subject matter is accordingly considered both novel and inventive. All amendments are fully supported by the application as filed, in particular the Abstract, the Summary of the Invention, the Detailed Technical Description, the Recommended Dosage section and the Best Mode; no new matter has been added (Article 19(2)). The amendments have no impact on the description or the drawings.
